Clinical Trials Logo

Clinical Trial Summary

This study aims to investigate the safety and efficacy of radiotherapy combined with Toripalimab (PD-1 inhibitor) in the treatment of locally advanced adenocarcinoma of the gastroesophageal junction.


Clinical Trial Description

In this study, patients with locally advanced adenocarcinoma of gastroesophageal junction will be enrolled to explore the safety and efficacy of preoperative radiotherapy and chemotherapy combined with Toripalimab (PD-1). Around 45 patients will be recruited in this one-arm cohort. All patients in this cohort will be treated with preoperative radiotherapy and chemotherapy plus PD-1 for two times, then another two times of PD-1 before operation. After surgery, postoperative chemotherapy plus PD-1 will be carried out for four times. This study focuses on the safety of chemoradiotherapy combined with immunotherapy, and whether the TRG grade, LC, DFS have been improved. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04061928
Study type Interventional
Source Peking University
Contact Jianhao Geng, MD
Phone +86-18500227857
Email gengjh3@sina.com
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date August 26, 2019
Completion date August 25, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT05161572 - Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer Phase 2
Completed NCT02399306 - Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma Phase 3
Recruiting NCT03286348 - Analysis of Nutrition During Chemoradiotherapy in Patients With Gastrointestinal Cancer N/A
Recruiting NCT04821765 - Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer Phase 2
Recruiting NCT04278287 - Chemoradiotherapy in Unresectable Esophageal Cancer Phase 1/Phase 2
Recruiting NCT05863260 - Tislelizumab Combing Chemoradiotherapy in Recurrent Cervical Cancer
Active, not recruiting NCT05027165 - Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab
Completed NCT04207918 - A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer Phase 2
Recruiting NCT06219083 - Nutrition and Cancer Outcomes in Shaanxi Chemoradiotherapy
Active, not recruiting NCT04764227 - Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17) Phase 2
Recruiting NCT06421376 - Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer Phase 2
Recruiting NCT05311566 - PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer Phase 2
Not yet recruiting NCT05286086 - Prehabilitation in Rectal Cancer: During Neoadjuvant Therapy vs Preoperative N/A
Recruiting NCT04772001 - Concurrent Radiochemotherapy Plus Anlotinib for Locally Advanced Cervical Cancer N/A
Recruiting NCT06410651 - Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma Phase 2
Recruiting NCT06429839 - Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients Phase 2
Recruiting NCT03177382 - Total Neoadjuvant Treatment vs. Chemoradiotherapy in Local Advanced Rectal Cancer With High Risk Factors Phase 3
Not yet recruiting NCT06413342 - Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma Phase 2
Completed NCT05590650 - A Pilot Study of Additional Chinese Formula for Concurrent Chemoradiotherapy in Oral Cavity Cancer Patients Phase 1
Recruiting NCT00973778 - A Study for Short Preoperative Chemoradiotherapy for Resectable Rectal Carcinoma Phase 2